It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Immune cells must adapt to different environments during the course of an immune response. Here we study the adaptation of CD8+ T cells to the intestinal microenvironment and how this process shapes the establishment of the CD8+ T cell pool. CD8+ T cells progressively remodel their transcriptome and surface phenotype as they enter the gut wall, and downregulate expression of mitochondrial genes. Human and mouse intestinal CD8+ T cells have reduced mitochondrial mass, but maintain a viable energy balance to sustain their function. We find that the intestinal microenvironment is rich in prostaglandin E2 (PGE2), which drives mitochondrial depolarization in CD8+ T cells. Consequently, these cells engage autophagy to clear depolarized mitochondria, and enhance glutathione synthesis to scavenge reactive oxygen species (ROS) that result from mitochondrial depolarization. Impairing PGE2 sensing promotes CD8+ T cell accumulation in the gut, while tampering with autophagy and glutathione negatively impacts the T cell pool. Thus, a PGE2-autophagy-glutathione axis defines the metabolic adaptation of CD8+ T cells to the intestinal microenvironment, to ultimately influence the T cell pool.
CD8+ T cells reprogram their metabolism in response to the gut environment. Upon sensing of PGE2, gut CD8+ T cells reduce their mitochondrial content, an event that ultimately shapes the pool of CD8+ T cells in the intestinal tissue.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Medical University of Graz, Division of Rheumatology and Immunology, Department of Internal Medicine, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476)
2 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
3 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); University Medical Center Freiburg, Department of Medicine I (Hematology and Oncology), Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911)
4 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Center for Molecular Medicine (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Institute for Genetics, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
5 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Siena, Department of Medical Biotechnology, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641)
6 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Trieste, Department of Life Sciences, Trieste, Italy (GRID:grid.5133.4) (ISNI:0000 0001 1941 4308)
7 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256)
8 University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911)
9 University Medical Center Freiburg, Department of Medicine II, Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6)
10 University Medical Center Freiburg, Department of Medicine I (Hematology and Oncology), Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6)
11 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6); University of Freiburg, Faculty of Biology, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); Johns Hopkins University, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
12 Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); Johns Hopkins University School of Medicine, Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); CIBSS Centre for Integrative Biological Signalling Studies, Freiburg, Germany (GRID:grid.517353.6); Johns Hopkins University, Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)